Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Flux Power Holdings Inc (FLUX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Flux Power Holdings Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $288.3 (market cap $39.89B), while Flux Power Holdings Inc trades at $0.79 (market cap $16.65M). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 2395.8× Flux Power Holdings Inc's market cap. Which is the better fit depends on your goals.
| ALNY | FLUX | |
|---|---|---|
Market Cap | $39.89B | $16.65M |
Sector | Health | Utilities |
52-Week High | $491.22 | $6.66 |
52-Week Low | $278.09 | $0.73 |
Enterprise Value | $38.15B | $22.81M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
FLUX trades at $0.7765, up 0.36% today, but technical indicators show a bearish trend with moving averages signaling sell. The company reported a net loss of $6.67 million in 2025, with revenue declining to $51 million in 2026, though it maintains a low P/S ratio of 0.29. Recent news highlights the launch of SkyEMS 3.0 AI software, aiming to boost operational efficiency for fleet customers.
Despite unanimous analyst buy ratings, FLUX faces significant profitability challenges with negative ROE and net margins. Investment appeal hinges on revenue stabilization and cost management, but high execution risk and cash flow volatility warrant caution for stock investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Flux Power Holdings Inc
Flux Power designs and manufactures lithium-ion battery packs for industrial vehicles. Its sustainable energy solutions power material handling equipment like forklifts and airport ground support vehicles.
Read more on FLUX →
